A share price of Cellectar Biosciences Inc [CLRB] is currently trading at $3.45, up 12.38%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CLRB shares have gain 20.63% over the last week, with a monthly amount glided 4.23%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ROTH Capital started tracking the stock assigning a Buy rating. Ladenburg Thalmann initiated its recommendation with a Buy and recommended $2.70 as its price target on December 21, 2016.
Cellectar Biosciences Inc experienced fluctuations in its stock price throughout the past year between $2.71 and $48.74. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Cellectar Biosciences Inc [NASDAQ: CLRB] shares were valued at $3.45 at the most recent close of the market. An investor can expect a potential return of 247.83% based on the average CLRB price forecast.
Analyzing the CLRB fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -2.12, Equity is -2.57 and Total Capital is -4.92. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.18 points at the first support level, and at 2.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.65, and for the 2nd resistance point, it is at 3.84.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cellectar Biosciences Inc [NASDAQ:CLRB] is 2.77. Also, the Quick Ratio is 2.77, while the Cash Ratio stands at 1.88.
Transactions by insiders
Recent insider trading involved CARUSO JAMES V, Chief Executive Officer, that happened on Jul 02 ’25 when 10000.0 shares were purchased. Chief Operating Officer, Longcor Jarrod completed a deal on Jul 02 ’25 to buy 10000.0 shares. Meanwhile, Chief Financial Officer Kolean Chad J bought 5000.0 shares on Jul 02 ’25.
